Clinical Guides
Uterine Fibroids
An India-focused, clinically focused guide to diagnosing and classifying uterine fibroids, treating bleeding and bulk symptoms, protecting fertility and recognising presentations that require urgent or specialist care.
MedNext Academy | 18 min read
Uterine Fibroids
An India-focused, clinically focused guide to diagnosing and classifying uterine fibroids, treating bleeding and bulk symptoms, protecting fertility and recognising presentations that require urgent or specialist care.
Summary
Uterine fibroids, also called leiomyomas or myomas, are benign smooth-muscle tumours of the uterus. They may be single or multiple and may project into the endometrial cavity, remain within the myometrium, extend toward the serosa or arise in less common locations such as the cervix. Their clinical importance depends more on size, number and relationship to the endometrium, serosa, bladder and bowel than on the word fibroid alone. Many are incidental and need no intervention. Symptomatic fibroids can cause heavy or prolonged menstrual bleeding, iron-deficiency anaemia, pelvic pressure, urinary frequency, constipation, pain, abdominal enlargement and reproductive difficulty.
Diagnosis is based on a coherent history plus imaging. Pelvic ultrasound is the first-line modality; hysteroscopy is particularly useful when a submucosal lesion or endometrial pathology is suspected, and MRI is reserved for complex mapping or procedure planning rather than routine confirmation. A fibroid on imaging does not prove that it causes every symptom. Pregnancy, adenomyosis, endometrial polyps, ovulatory dysfunction, coagulopathy, endometriosis and malignancy may coexist or provide a better explanation. Abnormal bleeding must be assessed according to age, pregnancy possibility and endometrial-cancer risk.
Treatment is driven by symptom burden, anaemia, fibroid phenotype, age, proximity to menopause and the patient's wish for future pregnancy or uterine preservation. Options range from observation and iron replacement to medicines that reduce bleeding, hysteroscopic resection, myomectomy, uterine artery embolisation and hysterectomy. Most bleeding medicines do not remove fibroids, and some suppressive therapies are suitable only for limited duration. Fertility decisions require special care because cavity-distorting fibroids behave differently from small subserosal lesions, while uterine artery embolisation is not equivalent to myomectomy for someone actively seeking pregnancy. This guide is educational, not a patient-specific prescription. A registered clinician must confirm diagnosis, product licensing, contraindications, procedure suitability and follow-up.
How Common Is It?
Fibroids are among the most common uterine tumours during reproductive life, but prevalence depends strongly on age, ancestry and how actively clinicians look for them. Imaging and pathology studies detect many small asymptomatic lesions that a symptom-based survey will miss. FIGO's 2025 diagnostic guidance cites lifetime estimates around three quarters in some studied populations, while emphasising that only a minority are symptomatic. That estimate should not be presented as an exact prevalence for every country or for India: ultrasound protocols, age structures, referral patterns and population ancestry differ, and India does not have a current national imaging-screen prevalence that justifies a single headline percentage.
Clinical burden is narrower than anatomical prevalence. FIGO's medical guidance describes abnormal uterine bleeding, anaemia, pelvic pain or pressure, back pain, urinary frequency, constipation and infertility among symptomatic presentations. Fibroids may be discovered during infertility work-up, antenatal ultrasound or imaging for an unrelated complaint. Symptoms do not correlate perfectly with total uterine size. A small intracavitary type 0 lesion may cause disproportionate bleeding, whereas a larger subserosal lesion may be silent or cause bulk symptoms without heavy bleeding.
Age is a major determinant. Fibroids are unusual before puberty, become more frequent through later reproductive years and often shrink after menopause as ovarian hormone exposure falls. Nevertheless, a new mass, growth or bleeding after menopause should not be assumed to be a routine fibroid. Symptoms can also change in pregnancy or with exogenous hormones. The population message is therefore not to screen every asymptomatic person with ultrasound. It is to recognise common symptom patterns, quantify their effect on quality of life, check for anaemia and investigate according to risk. In India, heavy menstrual bleeding is sufficiently important that ICMR and DHR provide a staged Standard Treatment Workflow across primary, secondary and tertiary care, including pregnancy exclusion, ultrasound, structural causes and referral.
Risk Factors
Fibroid development reflects acquired genetic changes in uterine smooth-muscle cells interacting with ovarian steroids, growth factors and extracellular matrix. Risk rises across the reproductive years until menopause. A first-degree family history and African ancestry are consistently associated with greater prevalence or earlier and more severe disease in international studies, but ancestry data should not be mechanically transferred into an Indian risk score. Earlier menarche, nulliparity or lower parity, obesity and hypertension have epidemiological associations. These are risk markers, not proof that an individual's behaviour caused a tumour. There is no validated diet, supplement or lifestyle programme that reliably dissolves established fibroids.
Oestrogen and progesterone support fibroid biology, but a single serum hormone measurement does not diagnose or predict growth. Pregnancy may alter size and can precipitate pain from degeneration, while many fibroids regress after menopause. Combined hormonal contraception and menopausal hormone therapy require an individual discussion rather than a blanket claim that they create fibroids. FIGO notes that combined oral contraceptives may control bleeding and have not been shown to universally promote fibroid growth. Postmenopausal hormone therapy can influence existing fibroids, so new symptoms or growth should be reassessed.
Risk of symptoms differs from risk of merely having a fibroid. Submucosal and cavity-distorting lesions are more strongly associated with heavy bleeding and impaired implantation than a small subserosal lesion. Larger or lower uterine fibroids may produce bladder, bowel or pressure symptoms. Multiple lesions complicate mapping and surgery. Baseline iron deficiency, anticoagulant use or a bleeding disorder can magnify menstrual loss even if the fibroid is not the only cause.
Leiomyosarcoma is rare and is not simply the expected malignant transformation of a common fibroid. No symptom, growth rate or imaging sign alone reliably excludes it. Increasing age, postmenopausal status, prior pelvic radiotherapy and certain hereditary cancer syndromes can increase concern. The practical response is appropriate assessment of atypical features and careful tissue-removal planning, not alarming every patient with a benign-appearing lesion.
Diagnosis
The diagnostic goal is not merely to find a fibroid; it is to determine whether its phenotype plausibly explains the symptoms, identify coexisting disease, assess anaemia and pregnancy, and obtain the information needed for shared treatment decisions. Use FIGO terminology when possible so that location and cavity relationship are communicated consistently.
History
Describe bleeding by duration, frequency, flooding, clots, night changes, double protection and impact on work rather than relying only on the word heavy. Ask about intermenstrual or postcoital bleeding, last menstrual period, pregnancy possibility and contraception. Record pelvic pressure, pain, dysmenorrhoea, dyspareunia, abdominal enlargement, urinary frequency or retention, constipation and back symptoms. Ask about fatigue, breathlessness, palpitations or pica suggesting iron deficiency. Establish age, parity, pregnancy plans, infertility duration, prior miscarriage, previous imaging and treatment. Review anticoagulants, hormonal medicines, family bleeding history and endometrial-cancer risk. Acute pain, fever, syncope, postmenopausal bleeding or rapid functional decline changes urgency.
Examination
Assess pulse, blood pressure, pallor and haemodynamic stability when bleeding is active. Abdominal examination may detect a firm irregular pelvic mass or tenderness, but normal palpation does not exclude fibroids or predict their FIGO type. Perform speculum and bimanual examination when bleeding, discharge, pain or a pelvic mass makes it appropriate, with consent and a chaperone. Identify cervical lesions, active bleeding, uterine enlargement, mobility, adnexal masses and tenderness. Do not delay pregnancy testing or emergency referral for a ritual examination in an unstable patient.
Investigations
Obtain a full blood count for heavy menstrual bleeding; ferritin is useful when iron deficiency is suspected or the haemoglobin does not tell the whole story. Exclude pregnancy in reproductive-age patients when relevant, as the current ICMR-DHR workflow explicitly requires. Pelvic ultrasound, usually transvaginal when acceptable and transabdominal when needed for a large uterus or declined internal scan, is first line. Report number, three-dimensional size, location, cavity distortion, endometrial appearance and adnexa. Offer outpatient hysteroscopy when persistent intermenstrual bleeding or suspected submucosal fibroid, polyp or endometrial pathology makes direct cavity assessment appropriate. Endometrial sampling is risk-based and should be obtained in the proper diagnostic context, not as a blind universal test. Saline infusion sonography can refine cavity mapping where available. Reserve MRI for complex, indeterminate or numerous lesions and pre-procedure mapping. Renal imaging is appropriate if ureteric obstruction is suspected.
Differential Diagnosis
Use the FIGO PALM-COEIN framework for abnormal uterine bleeding. Structural alternatives or co-pathology are polyp, adenomyosis, malignancy or hyperplasia, while leiomyoma is the L category. Non-structural causes are coagulopathy, ovulatory dysfunction, endometrial causes, iatrogenic causes and not otherwise classified. Finding a fibroid does not remove these alternatives. A patient with irregular infrequent cycles and prolonged bleeding may primarily have ovulatory dysfunction; a patient with lifelong heavy bleeding and easy bruising may have a bleeding disorder; anticoagulation can amplify either.
Pregnancy-related diagnoses must be excluded when possible. Early intrauterine pregnancy, miscarriage, ectopic pregnancy and gestational trophoblastic disease can present with bleeding, pain or an apparent uterine mass. Adenomyosis often causes heavy painful periods with a bulky tender uterus and can coexist with fibroids. Endometrial polyps are a common intracavitary alternative. Endometriosis may better explain cyclical pain, deep dyspareunia or infertility. Pelvic inflammatory disease, tubo-ovarian pathology and urinary or gastrointestinal disease belong in the differential for pain or pressure. An ovarian mass can be mistaken clinically for a pedunculated subserosal fibroid; careful imaging should establish organ of origin.
Endometrial hyperplasia and cancer require attention with persistent intermenstrual bleeding, postmenopausal bleeding, obesity, chronic anovulation, diabetes, tamoxifen exposure or other risk factors. Cervical cancer or polyps can cause postcoital or irregular bleeding and require speculum assessment. Uterine sarcoma is rare, but concern rises with an atypical or heterogeneous mass, postmenopausal growth, necrosis, invasive features or systemic decline. Rapid growth by itself is neither sensitive nor specific, and a reassuring scan cannot absolutely exclude sarcoma.
For infertility, assess the couple rather than attributing delay automatically to fibroids. Age, ovulation, ovarian reserve where indicated, semen parameters and tubal factors matter. FIGO 2026 guidance distinguishes strong fertility effects from submucosal and cavity-distorting fibroids, more uncertain effects from many intramural lesions and minimal effect from small subserosal lesions. Treatment should follow the entire fertility assessment, not the presence of any myoma on a report.
Management
Asymptomatic fibroids with a typical imaging appearance usually need no treatment. Explain the finding, document baseline size and symptoms, and give a return plan for new bleeding, pain, pressure or postmenopausal change. Routine repeated imaging at arbitrary short intervals is not automatically beneficial; follow-up should reflect phenotype, uncertainty, reproductive plans and symptoms. For symptomatic disease, agree what success means: lighter bleeding and corrected iron deficiency, pain relief, reduced pressure, pregnancy preparation, uterine preservation or definitive treatment.
Treat iron deficiency alongside the cause. Use oral or intravenous iron according to severity, tolerance, time available and local protocol; acute haemodynamic compromise requires resuscitation and escalation. For bleeding control, options include tranexamic acid during menses, NSAIDs when pain and bleeding coexist, combined hormonal contraception, cyclical oral progestogens or an LNG-IUS when the cavity is suitable. These can improve bleeding without reliably shrinking the fibroid. A distorted cavity can impair LNG-IUS placement, retention or effectiveness. GnRH agonists can shrink fibroids and improve haemoglobin before surgery, but hypo-oestrogenic adverse effects and regrowth after stopping restrict duration. Oral GnRH antagonist combinations are emerging specialist options; verify Indian approval, availability and add-back requirements. Ulipristal acetate has severe liver-injury restrictions and should not be copied from a foreign guideline into Indian prescribing without current regulatory confirmation.
Match procedures to phenotype and goals. Hysteroscopic myomectomy is preferred for accessible submucosal fibroids causing bleeding and is often the fertility-preserving procedure for FIGO types 0 and 1 and selected type 2 lesions. Laparoscopic or open myomectomy preserves the uterus for selected intramural or subserosal disease but carries bleeding, adhesion, recurrence and future pregnancy considerations. Uterine artery embolisation can control bleeding and bulk symptoms without hysterectomy, but fertility and pregnancy outcomes must be discussed carefully; FIGO fertility guidance does not recommend it for patients actively seeking pregnancy. Image-guided focused ultrasound or ablation may be available in selected centres, with eligibility and long-term evidence varying.
Hysterectomy is definitive and eliminates recurrence, but it is major surgery and permanently ends uterine fertility. Route should be individualised. Before any tissue fragmentation, discuss the small possibility of occult malignancy and alternatives to uncontained power morcellation. Review medical treatment after an agreed interval, commonly three to six months, earlier for worsening bleeding, adverse effects or pregnancy plans. Failure of one option should trigger reassessment of diagnosis and priorities rather than automatic escalation down a fixed ladder.
Prescribing Information
This section is an educational prescribing framework, not a prescription. First confirm whether the immediate problem is stable cyclical heavy bleeding, acute ongoing haemorrhage, pain, anaemia, contraception need or preoperative preparation. Check pregnancy, haemodynamic status, haemoglobin, renal and liver considerations, thrombosis history, interacting medicines and the fibroid's relationship to the cavity. Use generic names and verify the current Indian label. A medicine that reduces menstrual loss does not necessarily shrink a fibroid or improve fertility.
Tranexamic acid is a non-hormonal antifibrinolytic taken only during bleeding. The December 2025 ICMR-DHR HMB workflow lists intravenous tranexamic acid 1 g slowly for an acute bleeding episode followed by oral 0.5 to 1 g every six to eight hours for five days. Intravenous treatment belongs in a monitored clinical pathway, not self-care. For stable outpatient use, select an oral regimen within the current label and local protocol, adjust for renal impairment, and avoid it in active thromboembolic disease or when the patient's history makes thrombosis risk unacceptable. Explain that it controls bleeding but does not reduce fibroid size.
The same Indian workflow lists cyclical oral progestogen options, including norethisterone or medroxyprogesterone acetate, in divided daily dosing from day five for three weeks and repeated for four to six cycles, with a stated maximum total daily dose of 40 mg. That workflow is a broad HMB pathway, not authority to prescribe the maximum automatically. Choose the lowest suitable regimen after checking contraindications, pregnancy plans, thrombotic and metabolic risk and current product information. Combined hormonal contraception may be reasonable when contraception is also desired, but assess age, smoking, migraine with aura, hypertension and venous-thromboembolic risk. An LNG-IUS can substantially reduce bleeding when the cavity is not materially distorted; counsel about early irregular bleeding, expulsion risk and the fact that fibroid volume may not fall.
NSAIDs may reduce dysmenorrhoea and menstrual loss but require gastrointestinal, renal, cardiovascular and asthma review. Do not combine or dose them casually. GnRH agonists are generally short-course specialist treatments, often before surgery; discuss hot flushes, bone loss and regrowth after cessation. GnRH antagonists with add-back therapy need specialist selection and India-specific licensing verification. Do not prescribe ulipristal acetate on the strength of older or foreign recommendations without checking current restrictions and liver-safety requirements.
Arrange a response and safety review. Recheck haemoglobin or iron indices when abnormal, assess bleeding and adverse effects, and revisit fertility goals. Escalate rather than repeatedly renewing medicine when bleeding remains severe, anaemia fails to correct, a cavity lesion needs removal or bulk symptoms predominate.
When to Refer
Refer immediately for haemodynamic instability, syncope, ongoing major blood loss, severe symptomatic anaemia, pregnancy-related bleeding or an acute abdomen. The ICMR-DHR workflow specifies higher-centre referral for acute ongoing loss or haemoglobin below 7 g/dL, but clinical escalation may be necessary at a higher value when symptoms, comorbidity, pregnancy, rate of decline or lack of local capability make outpatient treatment unsafe. New urinary retention, hydronephrosis, bowel obstruction, peritonism, sepsis or uncontrolled pain also requires urgent evaluation.
Refer promptly for postmenopausal bleeding, persistent intermenstrual or postcoital bleeding, a suspicious cervix, endometrial-cancer risk requiring hysteroscopy or sampling, or a mass with atypical imaging or postmenopausal growth. Gynaecological oncology or a sarcoma-capable multidisciplinary pathway is appropriate when malignancy is suspected. Do not perform uncontained tissue fragmentation in a mass that has not been appropriately assessed.
Specialist gynaecology referral is appropriate when symptoms impair quality of life despite initial care, anaemia recurs, diagnosis or organ of origin is uncertain, the uterus is markedly enlarged, fibroids distort the cavity, or a procedure is being considered. Current guidelines advises considering specialist care for fibroids 3 cm or larger because size, number, location and symptoms alter the balance among medicine, uterine artery embolisation, myomectomy and hysterectomy. Three centimetres is not an emergency threshold; a smaller submucosal lesion may warrant intervention, while an asymptomatic larger lesion may not.
Refer early to a fertility-focused gynaecologist or reproductive medicine service when pregnancy is desired and the lesion distorts the cavity, infertility is established, recurrent pregnancy loss is being investigated, access to the ovaries may be difficult or treatment might compromise ovarian or uterine function. Discuss myomectomy route and future pregnancy planning before surgery. Interventional radiology referral for uterine artery embolisation should include explicit reproductive counselling. Complex medical therapy, severe comorbidity, uncertain Indian drug availability or repeated treatment failure also justifies specialist input rather than improvised long-term suppression.
Red Flags
Acute bleeding red flags are fainting, confusion, chest pain, breathlessness at rest, persistent tachycardia, hypotension, pallor with functional collapse, soaking protection repeatedly over a short interval or passing large clots with ongoing loss. Stabilise, obtain pregnancy testing and blood count as appropriate, establish access and refer; do not wait for elective ultrasound in an unstable patient. Severe unilateral or lower abdominal pain with bleeding and pregnancy possibility requires urgent ectopic-pregnancy assessment.
Cancer-related red flags include any postmenopausal bleeding, a new or enlarging postmenopausal uterine mass, persistent intermenstrual or postcoital bleeding, offensive discharge, unexplained weight loss, a suspicious cervical or vulval lesion, progressive abdominal distension or atypical imaging with necrosis or invasion. Most fibroids are benign, and rapid growth alone does not diagnose sarcoma, but neither a previous fibroid label nor one reassuring feature should close the assessment. Tissue removed at surgery must follow appropriate histopathology pathways.
Pressure complications become urgent when there is acute urinary retention, oliguria, hydronephrosis, progressive renal impairment, bowel obstruction, severe leg swelling from venous compression or neurological compromise. Sudden severe pain with fever, guarding, vomiting or sepsis needs assessment for degeneration, torsion of a pedunculated lesion, infection, adnexal pathology or another surgical abdomen. Pain in pregnancy needs obstetric assessment because degeneration is only one possible explanation.
Treatment red flags include thromboembolic symptoms while using hormonal therapy or tranexamic acid, jaundice or marked liver symptoms with a hepatotoxic medicine, severe headache or focal neurological deficit, and uncontrolled bleeding despite treatment. A proposed uncontained power-morcellation plan without an age-appropriate malignancy assessment and informed discussion is a procedural safety red flag. Fertility is also time-sensitive: repeated short courses that postpone definitive cavity treatment in an older infertility patient may cause harm even without an emergency. Safety-net with specific symptoms, destination and timeframe rather than telling the patient simply to return if worse.
Indian Clinical Context
The December 2025 ICMR-DHR Standard Treatment Workflow for heavy menstrual bleeding is the most directly applicable current Government of India pathway used in this guide. It requires pregnancy exclusion in reproductive-age patients, stratifies assessment across primary, community and tertiary levels, includes haemoglobin and ultrasound, identifies fibroids and polyps as structural abnormalities, and prioritises counselling, conservative treatment and referral. It is advisory and must be interpreted with the individual patient's condition. Its one-page format cannot replace detailed fibroid mapping, fertility counselling or a surgical plan, so FIGO and international guidelines guidance fill those explicit gaps.
Access varies across India. A patient may have only transabdominal ultrasound locally, intermittent blood-bank access or long travel to hysteroscopy, MRI, interventional radiology or minimally invasive surgery. Record what the scan actually established rather than assigning a confident FIGO type from inadequate images. Stabilise bleeding and correct iron deficiency while arranging definitive assessment. Do not let inability to obtain MRI delay routine first-line ultrasound, and do not order expensive MRI when the result will not change management. Conversely, a complex uterus planned for myomectomy or embolisation deserves adequate mapping before intervention.
Use generic medicine names and confirm current Indian licensing, supply and affordability. Do not promote an imported brand or assume that a current guidelines technology appraisal establishes availability in India. Ulipristal restrictions and newer oral GnRH antagonist combinations are examples where a clinician must verify the Central Drugs Standard Control Organisation status, the Indian label and local access at the time of prescribing. Procedure counselling should cover local operator experience, transfusion capability, pathology services, expected recovery, recurrence, need for future caesarean delivery in selected myomectomy cases and realistic follow-up.
Anaemia can compound educational, work and caregiving burdens, so ask about function rather than waiting for a crisis threshold. Provide a written plan for acute bleeding and iron follow-up. Respect privacy, fertility preferences and the right to decline hysterectomy. Family involvement should occur only with the patient's consent. Teleconsultation can support results and counselling but should not replace examination for a mass, suspicious bleeding or instability. Referral networks should identify centres with hysteroscopy, fertility-sparing surgery, interventional radiology and oncological assessment instead of offering one locally familiar procedure as the only choice.
NMC Competency Mapping
This guide directly maps to the Competency Based Medical Education Curriculum 2024. Obstetrics and Gynaecology competency OG29.1 requires the learner to describe and discuss the aetiology, pathology, clinical features, differential diagnosis, investigations, principles of management and complications of fibroid uterus. A complete answer should identify leiomyoma as a benign smooth-muscle tumour, explain steroid-responsive growth without calling it a simple hormone excess, and classify lesions by their relationship to the endometrium and serosa. Clinical features should be organised into bleeding and anaemia, bulk or pressure, pain, reproductive effects and incidental disease.
OG24.1 integrates abnormal uterine bleeding: define and classify bleeding, use PALM-COEIN, and choose investigations and management. Fibroids are the AUB-L structural category, but the learner must not stop at the ultrasound finding. Pregnancy, coagulopathy, ovulatory dysfunction, endometrial causes, adenomyosis, polyps and malignancy remain important. A good clinical response assesses haemodynamic stability, quantifies functional impact, checks haemoglobin, selects ultrasound or hysteroscopy appropriately and recognises when endometrial evaluation is required.
The management component should be goal-based. Observation is appropriate for asymptomatic typical disease. Medicines can reduce bleeding or temporarily shrink lesions but do not all remove the cause. Match hysteroscopic myomectomy to submucosal lesions, abdominal or laparoscopic myomectomy to selected uterus-preserving cases, uterine artery embolisation to appropriately counselled patients and hysterectomy to those seeking definitive treatment. State that fertility desire, cavity distortion, size, number, location, anaemia, age and comorbidity alter the choice.
For bedside, OSCE or viva assessment, demonstrate consented abdominal and pelvic examination, interpretation of a structured ultrasound report, anaemia recognition, pregnancy exclusion and shared decision-making. Complications include severe bleeding, iron-deficiency anaemia, pressure on urinary or bowel structures, degeneration, torsion of a pedunculated lesion, infertility or adverse pregnancy effects, treatment complications and recurrence after uterus-sparing therapy. The graduate should recognise suspected malignancy and refer rather than claim that imaging can exclude every sarcoma.
Key Exam Pearls for NEET PG
Leiomyoma is a benign monoclonal smooth-muscle tumour with variable fibrous matrix. It is oestrogen- and progesterone-responsive, uncommon before puberty and often regresses after menopause. It is not correct to state that an ordinary fibroid routinely transforms into leiomyosarcoma. A postmenopausal mass or bleeding still needs evaluation because sarcoma can be difficult to distinguish before surgery. Red degeneration classically causes acute pain, often in pregnancy; torsion is possible in a pedunculated subserosal fibroid.
Know the FIGO types. Type 0 is a pedunculated intracavitary submucosal fibroid. Type 1 is submucosal with less than 50% intramural extension; type 2 has 50% or more. Type 3 is entirely intramural but contacts the endometrium. Type 4 is wholly intramural. Types 5 and 6 are subserosal with respectively 50% or more and less than 50% intramural components. Type 7 is pedunculated subserosal; type 8 denotes other locations such as cervical. A hybrid lesion can be described with two numbers. Cavity relationship often matters more for bleeding and fertility than maximum diameter alone.
Ultrasound is first-line. Use hysteroscopy for suspected intracavitary disease and MRI for complex mapping or procedure planning, not as the automatic first test. In heavy menstrual bleeding, obtain a full blood count and exclude pregnancy when relevant. Use PALM-COEIN: polyp, adenomyosis, leiomyoma, malignancy or hyperplasia; coagulopathy, ovulatory dysfunction, endometrial, iatrogenic and not otherwise classified.
Tranexamic acid reduces menstrual bleeding but does not shrink fibroids. LNG-IUS, combined hormonal contraception and progestogens mainly control bleeding; cavity distortion can reduce suitability of an intrauterine system. GnRH agonists shrink fibroids temporarily and can optimise haemoglobin before surgery, but hypo-oestrogenism and regrowth limit long-term use. Hysteroscopic myomectomy is suited to accessible submucosal lesions. Myomectomy preserves the uterus but fibroids can recur. Uterine artery embolisation is uterus-sparing but is not the preferred fertility treatment. Hysterectomy is definitive. Always align the answer with symptoms, FIGO type, anaemia, fertility plans and informed preference.
Frequently Asked Questions
Does every uterine fibroid need treatment or repeat scanning?
No. An asymptomatic fibroid with a typical imaging appearance usually needs explanation and symptom-based follow-up rather than automatic medicine, surgery or frequent scans. Treatment is considered when bleeding, anaemia, pain, pressure, fertility concerns, diagnostic uncertainty or organ compression is clinically important. Follow-up imaging is individualised to symptoms, menopausal status, phenotype and the planned intervention. New postmenopausal bleeding or growth, severe pain or worsening pressure should trigger reassessment rather than routine observation.
Can medicines permanently remove or dissolve uterine fibroids?
Most medicines used in routine care control heavy bleeding or pain without removing the fibroid. Tranexamic acid, NSAIDs, hormonal contraception, progestogens and an LNG-IUS primarily target symptoms. GnRH analogues can shrink fibroids temporarily, often before surgery, but adverse effects limit duration and regrowth commonly follows cessation. Claims that supplements or diets reliably dissolve fibroids are unsupported. Durable removal requires a procedure, and the appropriate choice depends on location, size, symptoms and fertility goals.
Do uterine fibroids always cause infertility or miscarriage?
No. The reproductive effect depends strongly on location and cavity distortion, and infertility requires assessment of both partners. Submucosal fibroids and lesions that distort the endometrial cavity are most consistently associated with reduced implantation and may benefit from myomectomy. Small subserosal lesions usually have little fertility effect, while evidence for many intramural fibroids is less certain. Age, ovulation, ovarian reserve when indicated, tubal patency and semen parameters must be assessed before attributing infertility to a scan finding.
When is heavy bleeding from fibroids an emergency?
Seek urgent care for fainting, confusion, chest pain, breathlessness at rest, rapid pulse, low blood pressure, repeated flooding over a short interval or ongoing large-volume loss. Pregnancy-related bleeding and severe pain require urgent assessment because ectopic pregnancy and other emergencies can mimic fibroid symptoms. The ICMR-DHR workflow directs higher-centre referral for acute ongoing blood loss or haemoglobin below 7 g/dL, but symptoms, comorbidity, pregnancy and rate of decline can require escalation at a higher haemoglobin.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic